Medicover Genetics Editorial Team|

Scientifically checkedView our editorial guidelines
Scientifically checked

May 23, 2025 — Medicover Genetics is proud to announce that its proprietary circulating tumor DNA-based minimal residual disease (MRD) assay has been utilized in a clinical study selected for presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

The interim results from the DART (Durvalumab After chemoRadioTherapy) study, to be presented by Professor Åslaug Helland from Oslo University Hospital, focus on patients with unresectable stage III non-small cell lung cancer (NSCLC) undergoing chemoradiotherapy followed by durvalumab consolidation therapy. The study utilizes Medicover’s proprietary ctDNA-based MRD assay, which forms part of its liquid biopsy platform, to monitor residual disease through serial blood sampling during the treatment course and surveillance.

The abstract (8011) will be presented on Sunday, June 1 at 4:42 PM CDT during the Rapid Oral Abstract Session on Lung Cancer in Hall D1, McCormick Place, Chicago.

For more information about the study, including the abstract, please visit .

Medicover will be represented at by Dr. Stefan Christoph Mehrle, Head of Business Unit Genetics, Dr. Alexia Eliades, Oncology Core Team Leader, Medicover Genetics, and Staffan Ternström, COO Diagnostic Services. For more information about Medicover Genetics, please visit medicover-genetics.com.

About Professor Åslaug Helland and the “Translational Studies on Solid Tumours” group

Professor Åslaug Helland, MD, PhD, is a thoracic oncologist and Research Director at the Oslo Comprehensive Cancer Centre, and Professor at the University of Oslo. She leads the national centre for clinical cancer research (MATRIX) and several lung cancer projects in Norway, and heads several investigator-initiated trials, including the DART and IMPRESS-Norway studies.

The “Translational Studies on Solid Tumours” Group at Oslo University Hospital, focuses on lung, pancreatic, and pan-cancer projects (). The team uses advanced techniques on material from investigator initiated trials to identify prognostic and predictive biomarkers that improve treatment precision and reduce side effects, ultimately leading to better patient care.

For further information, please contact: Pepa Tanousis, Marketing and Communications Director, Medicover Genetics Cyprus,

Last updated: September 10, 2026

Latest articles

All about genetics
Health and well-being
Hereditary diseases

  • VERACITY

    New-generation non-invasive prenatal screening from week 9 of pregnancy, analysing fetal cell-free DNA in maternal blood to detect selected chromosomal abnormalities with high sensitivity and specificity for early and reliable prenatal risk assessment.

  • Pharmacogenomics

    Enabling personalised treatments for safer, more effective care through genetic insights that guide optimal prescribing from the start and refine therapy when patients experience side effects or poor response.

  • ebiom+

    A comprehensive assessment of the endometrial microbiome and chronic endometritis pathogens to enhance clinical outcomes, prevent treatment delays, and support a more informed, personalised fertility care.

  • WES

    Advanced sequencing that simultaneously analyses a broad range of genes to detect the genetic basis of complex diseases, improve diagnostic accuracy, and inform recurrence risk assessment for better clinical decision-making.

Why Medicover Genetics

Leader in genetic testing with >25 years of experience in counselling and diagnostics

Comprehensive CE-IVD kit portfolio and seamless Technology Transfer solution for laboratories of any size

End-to-end clinical workflow from sample processing to sequencing analysis and reporting

CAP- accredited, GMP- and ISO9001, 15189 and 13485 certified

Are you a patient?

Are you a physician?